CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Inclusion Criteria: * Histologically-confirmed, primary, invasive breast cancer diagnosed within 5 years of study entry. * Qualifying risk status, at diagnosis utilizing receptor testing by ASCO/CAP guidelines, meeting one of the following: * Histologically positive axillary lymph nodes * Primary tumor that is ER/PR/Her2 negative * Primary tumor that is ER+/Her2 negative/Lymph node negative with Breast Cancer Recurrence Score of ≥ 25 per the Genomic Health Oncotype DX breast cancer test * Evidence of residual disease in the breast on pathological assessment after neoadjuvant chemotherapy. * Patients must have completed all primary therapy (definitive surgery, (neo)adjuvant chemotherapy adjuvant radiation and/or Her2-directed therapy) for the index malignancy at least 4 weeks prior to study entry. All prior treatment-related toxicity must be resolved prior to study enrollment. Concurrent receipt of adjuvant endocrine and bone modifying agents is allowed per standard of care guidelines. * Bone marrow aspirate after completion of therapy demonstrates detectable DTCs (via IHC) * No evidence of recurrent local or distant breast cancer by physical examination, blood tests (CBC, LFTs, Alk Phos), or symptom-directed imaging, per NCCN guidelines. * Age ≥ 18 years * ECOG performance status 2 * No contraindications to the study medications or uncontrolled medical illness. * Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L, Hb \>9 g/dL * Adequate l…